Technical Analysis for XTLB - XTL Biopharmaceuticals Ltd.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| See historical XTLB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | 200 DMA Resistance | Bearish | 0.00% |
| Jan 18 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% |
| Jan 18 | Pocket Pivot | Bullish Swing Setup | 0.00% |
| Jan 18 | Wide Bands | Range Expansion | 0.00% |
| Jan 18 | Gapped Up | Strength | 0.00% |
| Jan 17 | Narrow Range Bar | Range Contraction | 2.69% |
| Jan 17 | Wide Bands | Range Expansion | 2.69% |
| Jan 16 | Narrow Range Bar | Range Contraction | 3.24% |
| Jan 16 | Inside Day | Range Contraction | 3.24% |
| Jan 16 | Wide Bands | Range Expansion | 3.24% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-26
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. It is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C. The company's lead drug candidate is recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma blood cancer, as well as for the treatment of severe anemia. The rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma blood cancer. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases, with focus on schizophrenia. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Herzliya, Israel.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more XTLB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 3.94 |
| 52 Week Low | 1.43 |
| Average Volume | 18,798 |
| 200-Day Moving Average | 1.9986 |
| 50-Day Moving Average | 2.2155 |
| 20-Day Moving Average | 1.8135 |
| 10-Day Moving Average | 1.904 |
| Average True Range | 0.1642 |
| ADX | 16.15 |
| +DI | 33.7146 |
| -DI | 24.9554 |
| Chandelier Exit (Long, 3 ATRs ) | 1.9074 |
| Chandelier Exit (Short, 3 ATRs ) | 1.9226 |
| Upper Bollinger Band | 2.1042 |
| Lower Bollinger Band | 1.5228 |
| Percent B (%b) | 0.67 |
| BandWidth | 32.059553 |
| MACD Line | -0.0704 |
| MACD Signal Line | -0.1 |
| MACD Histogram | 0.0296 |
| Fundamentals | Value |
|---|---|
| Market Cap | 9.86 Million |
| Num Shares | 5.16 Million |
| EPS | -1.10 |
| Price-to-Earnings (P/E) Ratio | -1.74 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 5.40 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.20 | ||||
| Resistance 3 (R3) | 2.22 | 2.14 | 2.15 | ||
| Resistance 2 (R2) | 2.14 | 2.07 | 2.13 | 2.13 | |
| Resistance 1 (R1) | 2.03 | 2.03 | 1.99 | 2.01 | 2.12 |
| Pivot Point | 1.95 | 1.95 | 1.94 | 1.94 | 1.95 |
| Support 1 (S1) | 1.84 | 1.88 | 1.80 | 1.82 | 1.70 |
| Support 2 (S2) | 1.76 | 1.84 | 1.75 | 1.69 | |
| Support 3 (S3) | 1.65 | 1.76 | 1.67 | ||
| Support 4 (S4) | 1.63 |
